Argenica Therapeutics Ltd Statistics
Want to see AU:AGN full AI Analyst Report?
Argenica Therapeutics Ltd (AGN) Stock Statistics & Valuation Metrics
Total Valuation
Argenica Therapeutics Ltd has a market cap or net worth of AUD 15.41M. The enterprise value is AUD 32.86M.
- Market Cap
- AUD 15.41M
- Enterprise Value
- AUD 32.86M
Share Statistics
Argenica Therapeutics Ltd has 128,456,710 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 128,456,710
- Owned by Insiders
- 0.11%
- Owned by Institutions
- ―
Financial Efficiency
Argenica Therapeutics Ltd’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -30.59%.
- Return on Equity (ROE)
- -0.23
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -30.59%
- Return on Capital Employed (ROCE)
- -1.20
- Revenue Per Employee
- 0
- Profits Per Employee
- -195.05K
- Employee Count
- 7
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Argenica Therapeutics Ltd is -11.32. Argenica Therapeutics Ltd’s PEG ratio is -0.62.
- PE Ratio
- -11.32
- PS Ratio
- 0.00
- PB Ratio
- 2.61
- Price to FCF
- -3.68
- Price to Operating Cash Flow
- -3.68
- PEG Ratio
- -0.62
Income Statement
In the last 12 months, Argenica Therapeutics Ltd had revenue of 0 and earned -1.37M in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -7.06M
- Pretax Income
- -5.34M
- Net Income
- -1.37M
- EBITDA
- -7.06M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -4.19M and capital expenditures 0, giving a free cash flow of -4.19M billion.
- Operating Cash Flow
- -4.19M
- Free Cash Flow
- -4.19M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Argenica Therapeutics Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.18%
- Earnings Yield
- -8.86%
Stock Price Statistics
- Beta
- 1.48
- 52-Week Price Change
- -52.00%
- 50-Day Moving Average
- 0.13
- 200-Day Moving Average
- 0.16
- Relative Strength Index (RSI)
- 50.07
- Average Volume (3m)
- 77.67K
Important Dates
Argenica Therapeutics Ltd upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Feb 10, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Argenica Therapeutics Ltd as a current ratio of 10.60, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.60
- Quick Ratio
- 10.60
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Argenica Therapeutics Ltd has paid -3.97M in taxes.
- Income Tax
- -3.97M
- Effective Tax Rate
- 0.74
Enterprise Valuation
Argenica Therapeutics Ltd EV to EBITDA ratio is -1.28, with an EV/FCF ratio of -2.16.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.28
- EV to Free Cash Flow
- -2.16
- EV to Operating Cash Flow
- -2.16
Balance Sheet
Argenica Therapeutics Ltd has AUD 6.36M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 6.36M billion.
- Cash & Marketable Securities
- AUD 6.36M
- Total Debt
- AUD 0.00
- Net Cash
- AUD 6.36M
- Net Cash Per Share
- AUD 0.05
- Tangible Book Value Per Share
- AUD 0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Argenica Therapeutics Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 81.00%
Scores
- Smart Score
- 6
- AI Score
- 45

